tiprankstipranks
Advertisement
Advertisement

BTAI Stock Latest News

BioXcel Therapeutics reports Q1 EPS (54c), consensus (49c)
The FlyBioXcel Therapeutics reports Q1 EPS (54c), consensus (49c)
21d ago
BTAI
Bioxcel Issues Warrants in Private Equity Financing Deal
PremiumCompany Announcements
Bioxcel Issues Warrants in Private Equity Financing Deal
2M ago
8K
BTAI
BioXcel Therapeutics enrolls first patients in BXCL501 trial
PremiumThe Fly
BioXcel Therapeutics enrolls first patients in BXCL501 trial
2M ago
BTAI
BioXcel Therapeutics: Undervalued Franchise with IGALMI PDUFA Catalyst Supports Buy Rating Despite Reduced Target
PremiumRatings
BioXcel Therapeutics: Undervalued Franchise with IGALMI PDUFA Catalyst Supports Buy Rating Despite Reduced Target
2M ago
BTAI
BioXcel Therapeutics price target lowered to $5 from $6 at H.C. Wainwright
PremiumThe Fly
BioXcel Therapeutics price target lowered to $5 from $6 at H.C. Wainwright
2M ago
BTAI
FDA Accepts BioXcel sNDA for At-Home IGALMI Use
PremiumCompany AnnouncementsFDA Accepts BioXcel sNDA for At-Home IGALMI Use
2M ago
8K
BTAI
BioXcel Therapeutics announces FDA acceptance of Igalmi sNDA
Premium
The Fly
BioXcel Therapeutics announces FDA acceptance of Igalmi sNDA
2M ago
BTAI
Morning Movers: AstraZeneca jumps following tozorakimab trial results
Premium
The Fly
Morning Movers: AstraZeneca jumps following tozorakimab trial results
2M ago
AGX
AZN
BioXcel Therapeutics reports Q4 EPS (58c), consensus (63c)
PremiumThe Fly
BioXcel Therapeutics reports Q4 EPS (58c), consensus (63c)
2M ago
BTAI
BioXcel Therapeutics initiated with a Buy at Rodman & Renshaw
PremiumThe Fly
BioXcel Therapeutics initiated with a Buy at Rodman & Renshaw
3M ago
BTAI
BioXcel Therapeutics Announces Registered Direct Equity Financing
PremiumCompany Announcements
BioXcel Therapeutics Announces Registered Direct Equity Financing
3M ago
8K
BTAI
BioXcel price target lowered to $6 from $10 at H.C. Wainwright
PremiumThe Fly
BioXcel price target lowered to $6 from $10 at H.C. Wainwright
3M ago
BTAI
BioXcel Therapeutics announces results from Phase 2 trial of BXCL501
PremiumThe FlyBioXcel Therapeutics announces results from Phase 2 trial of BXCL501
3M ago
BTAI
BioXcel Therapeutics announces results from Phase 2 trial of BXCL501
Premium
The Fly
BioXcel Therapeutics announces results from Phase 2 trial of BXCL501
3M ago
BTAI
BTAI Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
BTAI Upcoming Earnings Report: What to Expect?
3M ago
BTAI
BioXcel Therapeutics to host KOL roundtable on Alzheimer’s dementia
PremiumThe Fly
BioXcel Therapeutics to host KOL roundtable on Alzheimer’s dementia
4M ago
BTAI
BioXcel Highlights IGALMI At-Home Acute Agitation Opportunity
PremiumCompany Announcements
BioXcel Highlights IGALMI At-Home Acute Agitation Opportunity
4M ago
8K
BTAI
BioXcel completes updated market opportunity assessment for Igalmi
PremiumThe Fly
BioXcel completes updated market opportunity assessment for Igalmi
4M ago
BTAI
BioXcel sets milestone bonuses amid pivotal IGALMI review
PremiumCompany Announcements
BioXcel sets milestone bonuses amid pivotal IGALMI review
4M ago
8K
BTAI
One new option listing and option delistings on January 20th
PremiumThe FlyOne new option listing and option delistings on January 20th
5M ago
CVM
TEF
BioXcel seeks FDA approval for at-home IGALMI use
Premium
Company Announcements
BioXcel seeks FDA approval for at-home IGALMI use
5M ago
8K
BTAI
BioXcel Therapeutics submits sNDA to U.S. FDA for Igalmi
Premium
The Fly
BioXcel Therapeutics submits sNDA to U.S. FDA for Igalmi
5M ago
BTAI

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >